Three MS drugs stay cheap for patients — for now

About 33,000 Australians with multiple sclerosis can breathe easier. On 16 July 2026, Health Minister Mark Butler confirmed three MS drugs — Ocrevus, Kesimpta and Lemtrada — will stay on the PBS, the government scheme that makes medicines affordable. Butler says the evidence supports them. A final decision comes after a review finishes by end of 2026.